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Abstract
The membrane fusion protein of HIV-1 is the envelope transmembrane gp41 glycoprotein, which is the responsible of the membrane fusion
between the virus and the target cell. Gp41 has an unusual cytoplasmic tail, the endodomain, containing highly helicoidal segments with large
hydrophobic moments, the so called lentivirus lytic peptides or LLPs. According to our previous work, one of the most membranotropic regions
along the whole gp41 glycoprotein was located in the LLP3 region of the gp41. In order to get new insights into the viral membrane fusion
mechanism, a peptide pertaining to the LLP3 domain has been studied by infrared, fluorescence and calorimetry regarding its structure, its ability
to induce membrane rupture and aggregation, as well as its affinity towards specific phospholipids. Our results demonstrate that this peptide
interacts with phospholipid-containing model membranes, affects the phase-behavior of membrane phospholipids and induces leakage and
aggregation of liposomes. The membrane-perturbing properties of LLP3, together with the possibility that the Kennedy sequence could be part of
an external loop, open the possibility that these domains might function in modulating viral membrane fusion or budding, synergistically with
other membranotropic regions of the gp41 glycoprotein.
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The human immunodeficiency virus (HIV) causes the ac-
quired immunodeficiency syndrome by killing CD4 T-cells of
the host organism [1–3]. Trimers of gp41 transmembrane en-
velope glycoproteins, located on the viral envelope, enable
the entry of the viral capsid into the target cells by inducing
the formation of transient non-bilayer structures at the point
where both bilayers merge [1–4]. The gp41 sequence is highly
conserved [5] and it is composed by different functional regions
along the gp41 sequence that are critical for membrane fusion
(see Fig. 1) [6–10]. These regions of the gp41 glycoprotein
have the capabilities of binding and partitioning into the sur-
face of phospholipid model membranes, changing their confor-
mation and inducing the formation of non-lamellar structures,
indicating that these segments could play an essential role in
the viral fusion process [6–15].
Interestingly, both HIV-1 and SIV gp41 envelope glycopro-
teins, have an unusual cytoplasmic tail, the endodomain, which
Fig. 1. Schematic view of the organization of the whole sequence of HIV1 envelope gp41 glycoprotein (amino acid residues 515 to 856 for the full length) with one
membrane spanning domain showing the approximate structural and functional regions: fusion peptide (FP), N-heptad repeat (NHR), loop, C-heptad repeat (CHR),
pre-transmembrane (PTM), transmembrane (TM), Kennedy sequence, and the lentivirus lytic peptides (LLP-2, LLP-3 and LLP-1) as well as the corresponding
hydrophobic moment, hydrophobicity, and interfaciality distribution, assuming gp41 forms an α-helical wheel [74]. Both positive and negative bilayer-to-water
transfer free-energy values are shown. The sequence of the truncated-LLP3 peptide studied in this work is highlighted in the figure with dotted lines. The insert shows
the helical wheel representation of the truncated-LLP3 peptide.
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amino acids tail that have the rest of retroviruses [16]. The
cytoplasmic domain of gp41 has been implicated in several
functions including regulation of fusogenicity, replication,
infectivity, transmission, cytopathogenicity, uncoating, assem-
bly, etc. [17–26]. This large cytoplasmic tail of gp41 has three
amphipatic highly-helicoidal segments which have large hydro-
phobic moments, the so called lentivirus lytic peptides (LLP):
LLP1, which is located in residues 828–856 [27,28], LLP2,
located in residues 770–795 [29] and LLP3, located in residues
789–815 [30]. These regions could interact either with the inner
leaflet of the cellular membrane or with the HIV-1 envelope
or both according to the results obtained using synthetic pepti-
des corresponding to these regions [28,29,31]. It is also known
that LLP1 and LLP2 have a cytolitic effect on eukaryotic and
prokaryotic cells [27,28], but it is not known whether LLP3
has a cytolitic effect on eukaryotic and/or prokaryotic cells. On
the other hand, LLPs are involved in protein–protein interac-
tions. For instance, LLP1 interacts with calmodulin [32,33]
and LLP3 interacts with the carboxy-terminal regulatory do-
main of p115-RhoGEF, a specific guanine nucleotide exchange
factor (GEF) and activator of the RhoA GTPase [34].
Although much information has been gathered in recent years,
we do not know yet the different processes and mechanism
behind virus-host cell membrane fusion; in this way, elucidating
the nature of the interactions between membrane proteins and
membranes is important for its understanding. As far as we
know, only one biophysical study has been described to cha-
racterize the LLP3 peptide–lipid interaction [30]. For this reason
and because this region is one of the most membrane-active
regions along the whole gp41 glycoprotein according to our
previous work [11], we present here a biophysical study ofthe membrane interaction of a peptide derived from this region,
truncated-LLP3. It is the purpose of the present work to study this
peptide in the presence of different membrane model systems
composed of different phospholipid mixtures, to evaluate its
incorporation and location in the membrane model systems and
to study its effect on the integrity and phase behavior of the
membrane, as well on biological ones. Our results demonstrate that
this peptide binds and interacts with membranes which suggest that
it could be involved directly in merging of the viral and cellular
membranes and might work synergistically with other membrane-
active regions of the gp41 glycoprotein to boost the fusion process.
2. Materials and methods
2.1. Materials and reagents
The HIV-1 envelope protein gp41 fragment (truncated-LLP3) encompassing
residues 785–807 of strain HIVMN (
785LGRRGWEVLKYWWNLLQYWSQEL807)
was synthesized with C-terminal amide and N-terminal acetylation on an automatic
multiple synthesizer (Genemed Synthesis, USA). The peptides were purified by
reverse-phase HPLC (Vydac C-8 column, 250×4.6 mm, flow rate 1 ml/min, solvent
A, 0.1% trifluoroacetic acid, solvent B, 99.9 acetonitrile and 0.1% trifluoroacetic acid)
to better than 95% purity, and its composition andmolecular mass were confirmed by
amino acid analysis and mass spectroscopy. Since trifluoroacetate has a strong
infrared absorbance at approximately 1673 cm−1, which interferes with the charac-
terization of the peptide Amide I band [35], residual trifluoroacetic acid, used
both in peptide synthesis and in the high-performance liquid chromatography mo-
bile phase,was removed by several lyophilisation/solubilisation cycles in 10mMHCl
[36]. Egg L-α-phosphatidylcholine (EPC), egg sphingomyelin (SM), egg trans-ste-
rified L-α-phosphatidylethanolamine (TPE), bovine brain L-α-phosphatidylserine
(BPS), bovine brain L-α-phosphadidylinositol (BPI), 1,2-dimyristoyl-sn-glycero-
phosphatidylcholine (DMPC), 1,2-dimyristoyl-sn-glycero-phosphatidylglycerol
(DMPG), 1,2-dielaidoyl-sn-glycero-3-phosphoethanolamine (DEPE), 1,2-dimyris-
toyl-sn-glycero-phosphatidylserine (DMPS), 1,2-dimyristoyl-sn-glycero-phosphati-
dic acid (DMPA) and cholesterol (Chol) were obtained from Avanti Polar Lipids
Fig. 2. (A) Change on the tryptophan fluorescence of the truncated-LLP3 peptide in the presence of increasing lipid concentrations, (B) Doxyl NS quenching (5NS,
open symbols, and 16NS, black symbols) of the tryptophan fluorescence of the truncated-LLP3 peptide in the presence of LUVs at different lipid compositions and
(C) Acrylamide quenching studies of the tryptophan fluorescence of the truncated-LLP3 peptide in aqueous solution (♦) and in the presence of LUVs having different
lipid compositions (C). The lipid compositions used were EPC/Chol at a molar ratio of 5:1 (■), EPC/SM/Chol at a molar ratio of 5:1:1 (▲), EPC/TPE/Chol at a molar
ratio of 5:3:1 (▼) and EPC/BPS/Chol at a molar ratio of 5:4:1 (●). Vertical bars indicate standard deviations of the mean of triplicate samples.
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phosphoethanolamine (N-RhB-PE) and N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-1,2-
dihexadecanoyl-sn-glycero-3-phosphoethanolamine (NBD-PE) were obtained from
Molecular Probes Inc. (Eugene, OR, USA). 5-doxyl-stearic acid (5NS), 16-doxyl-
stearic acid (16NS) and 5-carboxyfluorescein (CF) (N95% by HPLC) were from
Sigma-Aldrich (Madrid, ES, EU). Sodium dithionite was from Fluka (Darmstadt,
GER, EU). All other chemicals were commercial samples of the highest purity
available (Sigma-Aldrich, Madrid, ES, EU). Water was deionized, twice-distilled
and passed through a Milli-Q equipment (Millipore Ibérica, Madrid, ES, EU) to a
resistivity better than 18MΩ.cm.
2.2. Sample preparation
Aliquots containing the appropriate amount of lipid in chloroform/methanol
(2:1, v/v) were placed in a test tube, the solvents removed by evaporation under a
stream of O2-free nitrogen, and finally, traces of solvents were eliminated under
vacuum in the dark for more than 3h. The lipid films were resuspended in an
appropriate buffer and incubated either at 25 °C or 10 °C above the phase transition
temperature (Tm) of the phospholipid mixture with intermittent vortexing for 30
min to hydrate the samples and obtain multilamellar vesicles (MLV). Afterwards,
the samples were frozen and thawed five times to ensure complete homogenization
and maximization of peptide/lipid contacts with occasional vortexing. Large
unilamellar vesicles (LUV) with a mean diameter of 0.1 μm were prepared from
multilamellar vesicles by the extrusion method [37] using polycarbonate filters
with a pore size of 0.1 μm (Nuclepore Corp., Cambridge, CA, USA). Small
unilamellar vesicles (SUV)were prepared fromMLVs using aBranson250 sonifier
(40W) equipped with a titanium microtip until the suspension became completely
transparent. Every 30s, the samples were cooled for 90s in ice to prevent
overheating of the solution. The titanium particles released from the tip were
removed by centrifugation at 15000rpm at room temperature for 15min. The
phospholipid and peptide concentration were measured by methods described
previously [38,39]. Because of the high hydrophobicity of the truncated-LLP3
peptide, it was dissolved in buffer containing 50% DMSO. The maximum DMSO
concentration in the final solution was always lower than 1%.
2.3. Peptide binding to vesicles
The partitioning of the peptide into the phospholipid bilayer was monitored
by the fluorescence enhancement of tryptophan. Fluorescence spectra were
recorded in a SLM Aminco 8000C spectrofluorometer with excitation and
emission wavelengths of 290 and 338 nm, respectively, and 4 nm spectral
bandwidths. Measurements were carried out in 10 mM Tris–HCl and 100 mMNaCl, pH 7.4. Intensity values were corrected for dilution, cross-oriented
polarizers (Empol=0°, Expol=90°) were used to minimize the scattering
background and the procedure of subtracting a scattering spectrum obtained
from a blank vesicle-containing sample from the fluorescence of vesicle-bound
peptide was followed. Partitioning coefficients were obtained using [40],
I
I0
¼ 1þ Imax
I0
 1
 
k L½ 
W½  þ k L½ 
 
where k is a mole fraction partition coefficient that represents the amount of
peptide in the bilayers as a fraction of the total peptide present in the system, Imax
is a variable value for the fluorescence enhancement at complete partitioning
determined by fitting the equation to the experimental data, [L] is the lipid
concentration, and [W] is the concentration of water (55.3M).
2.4. Acrylamide quenching of Trp emission
For acrylamide quenching assays, aliquots from a 4M solution of the water-
soluble quencher were added to the solution containing peptide in the presence
and absence of liposomes at a peptide/lipid molar ratio of 1:300. Measurements
were carried out in 10 mM Tris–HCl and 100 mM NaCl, pH 7.4. Intensity
values were corrected for dilution, and cross-oriented polarizers (Empol=0°,
Expol=90°) were used to minimize the scattering background and the procedure
of subtracting a scattering spectrum obtained from a blank vesicle-containing
sample from the fluorescence of vesicle-bound peptide was followed. The data
were analyzed according to the Stern–Volmer equation [41],
I0
I
¼ 1þ KSV Q½ 
where I0 and I represent the fluorescence intensities in the absence and in the
presence of the quencher [Q], respectively, and Ksv is the Stern-Volmer
quenching constant, which is a measure of the accessibility of Trp to acrylamide.
The excitation and emission wavelengths were 290 and 338 nm, respectively
and 4 nm spectral bandwidths.
2.5. Fluorescence quenching by lipophilic probes
Quenching studies with lipophylic probes were performed by successive
addition of small amounts of 5NS or 16NS in ethanol to the samples of the
peptide incubated with LUV. The final concentration of ethanol was kept below
2% (v/v) to avoid any significant bilayer alterations. After each addition an
incubation period of 15 min was kept before the measurement. The effective
Table 1
Partition coefficients and Stern–Volmer quenching constants for the truncated-LLP3 peptide in buffer and incorporated in LUVs of different compositions
LUV compositions KP KSV (M
−1) 5-NS KSV (M
−1) 16-NS KSV (M
−1) acrylamide
EPC/Chol (5:1) 2.02±0.93±106 19.27±1.10 13.71±0.67 6.46±0.87
EPC/SM/Chol (5:1:1) 1.91±0.92±106 24.35±1.13 18.67±0.67 6.42±0.43
EPC/TPE/Chol (5:3:1) 2.01±0.86±106 25.80±1.32 11.24±0.72 6.15±0.15
EPC/BPS/Chol (5:4:1) 4.94±0.99±107 18.35±1.29 8.34±0.62 7.57±0.32
Truncated-LLP3 in buffer – – – 12.01±0.02
Peptide/lipid ratio of 1:300.
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following relationship [42],
Q½ L ¼ Q½ T 1
KP;QgL L½ 
1 gL L½  þ KP;QgL L½ 
 
KP;Q
1 gL L½ 
where γL is the phospholipid molar volume, [Q]T is the total quencher con-
centration, [L] is the lipid molar concentration and KP,Q is the partition co-
efficient of the quencher. The KP,Q values for 5NS and 16NS were as reported
previously [43]. The fluorescence data were analyzed using a direct fit according
to the following relationship [44],
I0
I
¼ 1þ KSV Q½ L
1þ KSV Q½ L
 
1 fBð Þ þ fB
where I0 is the fluorescence intensity in the absence of quencher, KSV is the
Stern–Volmer quenching constant, and fB= I0,B / I0, where I0,B is the fluo-
rescence intensity of the fluorophore population accessible to the quencher. The
excitation and emission wavelengths were 290 and 338 nm, respectively and
4 nm spectral bandwidths.
2.6. Membrane rupture (leakage) measurement
LUVs with a mean diameter of 0.1 μm were prepared as indicated above in
buffer containing 10 mM Tris–HCl, 20 mM NaCl, 0.05 mM EDTA, pH 7.4, and
CF at a concentration of 40 mM. Non-encapsulated CF was separated from the
vesicle suspension through a Sephadex G-75 filtration column (Pharmacia,
Uppsala, SW, EU) eluted with buffer containing 10 mM Tris, 100 mM NaCl,
0.05 mM EDTA, pH 7.4. Membrane rupture (leakage) of intraliposomal CF was
assayed by treating the probe-loaded liposomes (final lipid concentration 75 μM)
with the appropriate amounts of peptide in a 5 mm×5 mm fluorescence cuvette
stabilized at 25 °C under constant stirring, with a final volume of 400 μl. Changes
in fluorescence intensity were recorded on a Varian Cary Eclipse fluorescence
spectrometer with excitation and emission wavelengths set at 492 and 517 nm,
respectively. Excitation and emission slits were set at 5 nm One hundred per-
cent release was achieved by adding Triton X-100 to a final concentration of
0.5% (w/w) to the fluorescence cuvette. Fluorescence measurements were
made initially with probe-loaded liposomes, afterwards by adding peptide
solution and finally adding Triton X-100 to obtain 100% leakage. Leakage was
quantified on a percentage basis according to the equation,
k L ¼ Ff  F0ð Þ  100
F100  F0
being Ff the equilibrium value of fluorescence after peptide addition, F0 the
initial fluorescence of the vesicle suspension and F100 the fluorescence value
after addition of Triton X-100.
2.7. Thioflavin T assays for peptide aggregation
Peptide aggregation was assayed by using Thioflavin T (ThT). Thioflavin
T associates rapidly with aggregated peptides living rise a new excitation
maximum at 450 nm and a enhanced emission at 482 nm [45]. Buffer contai-
ned 100 mM NaCl, 10 mM Tris–HCl, 25 μM ThT, pH 7.4, either SDS (final
concentration of 8 mM) or LUVs (final phospholipid concentration of 0.5 mM)
and a peptide concentration of 5 μM. Fluorescence was measured before and
after the desired amount of peptide was added into the cuvette using a VarianCary Eclipse fluorescence spectrometer. Temperature was controlled with a
thermostatic bath at 25 °C under constant stirring. Samples were excited at
450 nm (slit width, 5 nm) and fluorescence emission was recorded at 482 nm
(slit width, 5 nm). Aggregation was quantified on a percentage basis according
to the equation,
k A ¼ Ff  F0ð Þ  100
Fmax  F0
where Ff is the value of fluorescence after peptide addition, F0 the initial
fluorescence in the absence of peptide and Fmax is the fluorescence maximum
obtained immediately after peptide addition.
2.8. Stopped-flow measurements
The kinetics of binding and peptide aggregation-disaggregation were studied
by diluting the 10 or 5 μM peptide solution (resuspended in aqueous buffer
100 mM NaCl and 10 mM Tris, pH 7.4) in buffer containing 400 μM LUVs
of POPC or 400 μM LUVs of POPC (400 μM) and ThT (50 μM). The reactions
were monitored by fluorescence above 320 nm (excitation at 290 nm) for
binding assays or above 530 nm (excitation at 482 nm) for aggregation–
disaggregation assays. In both cases an Applied Photophysics π*-180 stopped-
flow instrument equipped with a 100 μl cells and operating at the 1:1 mixing
ratio was used. Each reaction was measured at least 5 times. The kinetic traces
were averaged and analyzed using Origin software.
2.9. Differential scanning calorimetry
MLVs were formed as stated above in 100 mM NaCl, 0.05 mM EDTA and
25 mMHEPES, pH 7.4. The peptides were added to obtain a peptide/lipid molar
ratio of 1/15. The final volume was 1.2 ml (500 μM lipid concentration), and
was incubated 10 °C above the Tm of each phospholipid for 1 h with occasional
vortexing. Samples were degassed under vacuum for 10–15 min with gentle
stirring, prior to being loaded into the calorimetric cell. DSC experiments were
performed in a VP-DSC differential scanning calorimeter (MicroCal LLC, MA)
under a constant external pressure of 30psi in order to avoid bubble formation,
and samples were heated at a constant scan rate of 60 °C/h. Experimental data
were corrected from small mismatches between the two cells by subtracting a
buffer baseline prior to data analysis. The excess heat capacity functions were
then analyzed by using Origin 7.0 (Microcal Software). The error in the de-
termination of Tc and ΔH was 0.2 °C and 0.5 kJ/mol, respectively. The
thermograms were defined by the onset and completion temperatures of
the transition peaks obtained from heating scans. In order to avoid artifacts due
to the thermal history of the sample the first scan was never considered. Second
and further scans were carried out until a reproducible and reversible pattern
was obtained, what usually occurred already with the second scan.
2.10. Infrared Spectroscopy
Approximately 25 μl of a pelleted sample in D2O were placed between two
CaF2 windows separated by a 56-μm thick Teflon spacers in a liquid
demountable cell (Harrick, Ossining, NY). The spectra were obtained in a
Bruker IFS55 spectrometer using a deuterated triglycine sulfate detector. Each
spectrum was obtained by collecting 200interferograms with a nominal
resolution of 2 cm−1, transformed using triangular apodization and, in order
to average background spectra between sample spectra over the same time
Fig. 3. Effect of the truncated-LLP3 peptide on membrane rupture, i.e., leakage,
of LUVs containing different lipid compositions at different peptide-to-lipid
molar ratios. LUVs were composed of EPC/Chol at a molar ratio of 5:1 (■),
EPC/SM/Chol at a molar ratio of 5:1:1 (▲), EPC/TPE/Chol at a molar ratio of
5:3:1 (▼) and EPC/BPS/Chol at a molar ratio of 5:4:1 (●). Vertical bars indicate
standard deviations of the mean of triplicate samples.
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spectra. The spectrometer was continuously purged with dry air at a dew point of
– 40 °C in order to remove atmospheric water vapour from the bands of interest.
All samples were equilibrated at the lowest temperature for 20 min before
acquisition. An external bath circulator, connected to the infrared spectrometer,
controlled the sample temperature. For temperature studies, samples were
scanned using 2 °C intervals and a 2-min delay between each consecutive scan.
Subtraction of buffer spectra taken at the same temperature as the samples was
performed interactively using either GRAMS/32 or Spectra-Calc (Galactic
Industries, Salem, MA) as described previously [8,12]. Frequencies at the centre
of gravity, when necessary, were measured by taking the top 10 points of each
specific band and fitted to a Gaussian band. The criterion used for buffer
subtraction in the C=O and amide regions was the removal of the band near
1210 cm−1, and a flat baseline between 1800 and 2100 cm−1. Band-narrowing
and curve-fitting were applied as previously reported [46,47]).
Circular dichroism spectroscopy. SUVs were prepared in 100 μM phosphate,
pH 7.4. Different concentrations of trifluoroethanol (TFE) and SUVs of POPC to
attain different peptide-to-lipid ratios were added to the corresponding samples.
Spectra weremeasured at 25 °C on a Jasco J-810 CD spectropolarimeter fittedwith
a thermostatically controlled cell holder and interfaced with a Neslab RTE-111
water bath, using a 2 mm pathlength cell. Wavelength spectra were acquired every
0.2 nm at a scan speed of 50 nm±min−1 with a response time of 2s and averaged
over five scans at 25 °C from 250 to 190 nm, with a bandwidth of 2 nm. Secondary
structure predictions were estimated using the software CDNN 2.1 [48].
3. Results
We have shown recently the existence of different membra-
notropic regions on the HIV-1 gp41 envelope glycoprotein ecto
and endodomains by using a library of 15-mer peptides en-
compassing the full sequence of the gp41 envelope glycoprotein
[11]. One of the most membranotropic regions along the whole
gp41 glycoprotein was located in the LLP3 region of the gp41,
and since this region could be important in the membrane fusion
process we present here the results of the study of the interaction
with model membranes of a peptide derived from this region, the
truncated-LLP3 peptide (see Fig. 1).
The ability of the truncated-LLP3 peptide to interact with
membranes was determined from the increase in fluorescence
emission intensity of its Trp residues in the presence of model
membranes containing different phospholipid compositions at
different lipid/peptide ratios (Fig. 2A). The quantum yield of aTrp residue of a peptide or protein normally changes when this
amino acid is located in a more hydrophobic environment such
as a phospholipid membrane, normally increasing the intensity
of the fluorescence emission. In addition, the maximal spectral
position normally shifts toward shorter wavelengths at the same
time [9]. The Trp fluorescence intensity of the truncated-LLP3
peptide increased upon increasing the lipid/peptide ratio,
indicating a significant change on the environment of the Trp
moieties of the peptide (Fig. 2A). From data fitting, partition
coefficients, Kp, were obtained for the different phospholipid
compositions (summarized in Table 1). Kp values in the range
106–107 were obtained for the different phospholipid composi-
tions studied (Table 1) indicating that the peptide was bound to
the membrane surface with very high affinity [8,9,46,49]. A
higher Kp value was obtained for EPC/BPS/Chol phospholipid-
containing bilayers than those corresponding to the other studied
liposomes; similar results were obtained for another anionic
composition (POPC/POPG at a molar ratio of 85:15) (data not
shown). The truncated-LLP3 peptide has a positive net formal
charge of + 1, so that an electrostatic effect might be the reason to
observe higher Kp values compositions containing negatively
charged phospholipids.
The transverse location (penetration) of the truncated-LLP3
peptide into the lipid bilayer was evaluated by monitoring the
relative quenching of the fluorescence of the Trp residues by the
lipophylic spin probes 5NS and 16NS when the peptide was
incorporated in vesicles having different phospholipid composi-
tions (Fig. 2B). It can be seen that, in general and for each one of
the different membrane compositions studied, the truncated-
LLP3 peptide was quenched more efficiently by 5NS, quencher
for molecules near or at the interface, than by 16NS, quencher
for molecules buried deeply in the membrane, suggesting that
the truncated-LLP3 peptide remained close to the lipid/water
interface. We also studied the accessibility of the tryptophan
residues of membrane-bound truncated-LLP3 peptide towards
acrylamide, a neutral, water-soluble, highly efficient quenching
molecule, which is unable to penetrate into the hydrophobic core
of the lipid bilayer. The quenching data is presented in Fig. 2C
and the lower KSV values obtained in the presence of lipids
compared with the measurements in their absence (Table 1),
suggest that the truncated-LLP3 peptide is buried in the mem-
brane, becoming less accessible for quenching by acrylamide.
Linear Stern–Volmer plots are indicative of all Trp residues
being accessible to acrylamide, and in all cases, the quenching of
the peptide Trp residues showed acrylamide dependent con-
centration behavior. Interestingly, the KSV value in the presence
of negatively-charged phospholipids was slightly greater than in
the presence of zwitterionic ones, indicating that the peptide
would be located less deeply inside the membrane in the
presence of negatively-charged phospholipids.
In order to explore the effect of the truncated-LLP3 peptide in
the destabilization of membrane vesicles, we studied their effect
on the release of encapsulated fluorophores inmodel membranes
which were made up of different lipid compositions. The extent
of leakage observed at different peptide to lipid molar ratios and
the effect on different phospholipid compositions is shown in
Fig. 3, where it is observed that the peptide had a significant
Fig. 4. (A) Fluorescence variation of ThT after addition of the truncated-LLP3 peptide to an aqueous solution (1) and in the presence of LUVs of POPC at a lipid/
peptide molar ratio of 80:1 (2) and 40:1 (3) and (B) time-dependent increase of the fluorescence of tryptophan residues of the truncated-LLP3 peptide (a) and time-
dependent fluorescence variation of ThT (b) in the presence of LUVs of POPC at a lipid/peptide molar ratio of 80:1. (C) Same as B, but the lipid/peptide molar ratio
was 40:1.
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These leakage values are similar to others observed for known
cytolytic peptides such as melittin, alamethicin, maganin, etc.
[50–54]. The most important leakage value was observed in the
presence of liposomes composed of EPC/SM/Chol, where 100%
of leakage was reached at a molar lipid/peptide ratio of 250,
whereas the less leakage value was obtained for the EPC/BPS/
Chol composition, needing at least a 75:1 molar lipid/peptide
ratio to get 100% of leakage. The lower leakage value observed
in the presence of negatively-charged phospholipids might be
due to the fact the positively-charged peptide has an increased
affinity for negatively-charged liposomes, favoring an upper
location of the peptide at the membrane interface which in turn is
less active to provoke membrane leakage [55]. Nevertheless, the
peptide-to-lipid ratio required to observe a significant leakage
value was very low for all lipid compositions tested.
The truncated-LLP3 peptide aggregation state was assayed
using ThT [45], in order to know the possible effect of the
aggregation of the peptide on its effect on the membranes. As
observed in Fig. 4A, the peptide remained aggregated in an
aqueous medium, as the fluorescence change increased
dramatically after adding the peptide from a peptide stock
resuspended in DMSO. The presence of POPC provoked a fast
and progressive peptide disaggregation, although not a whole
one, since about 20% of the peptide remained in an aggregated
state. Furthermore, we studied the intrinsic relationship between
the kinetic process of peptide disaggregation with the interac-
tion of the peptide with the membrane by using stopped-flow as
shown in Fig. 4B and C. As observed in these figures, the
disaggregation process was intimately related to the interaction
of the peptide with the membrane, since the increase in the
fluorescence intensity of the Trp residues of the truncated-LLP3
peptide occurred concomitantly with the decrease in ThT
fluorescence. It could be interpreted as that the peptide insertion
into the membrane was taking place at the same time that the
peptide was disaggregating. In the first instance, the fluores-
cence of ThT increased without an increase in the fluorescence
of the Trp residues of the peptide, but after approximately
10seconds, the fluorescence of ThT decreased at the same rate
that the fluorescence of the Trp residues increased. Thesedata would indicate that the insertion of the peptide into the
membrane could occur when the peptide were in a monomeric
form.
The effect of the peptide on the thermotropic phase behavior
of different phospholipid multilamellar vesicles was assayed
using differential scanning calorimetry (DSC) and the corre-
sponding profiles are shown Fig. 5. Increasing the concentra-
tion of the truncated-LLP3 peptide in DEPE progressively
made the main gel-to-liquid transition, Lβ–Lα, to broaden and
shift slightly to lower temperatures (about 3 °C, see Fig. 5A).
Significantly, at a lipid/peptide ratio of 20:1 the main transition
was apparently made by different peaks, which should be due
to mixed phases. In contrast, the liquid-hexagonal transition,
Lα–HII, was broadened and shifted to higher temperatures; at
the highest peptide concentration used, the liquid-hexagonal
transition was no longer observed (insert, Fig. 5A). It is known
that both DMPC and DMPG MLVs which have not been
extensively annealed at low temperatures display two endother-
mic peaks on heating, the pre-transition (12–14 °C, Lβ′–Pβ′)
and the main transition (24 °C, Pβ′–Lα). As illustrated in
Fig. 5B and C, incorporation of the truncated-LLP3 peptide
significantly alter the thermotropic behavior of both DMPC and
DMPG, since the peptide abolished completely the pre-
transition of both phospholipids, even at a low lipid/peptide
ratio of 40:1 and 100:1, respectively. At increasing peptide
concentrations, the main gel-to-liquid transition was signifi-
cantly broadened and shifted to lower temperatures and at the
same time, two peaks at least were evident. In contrast to both
DMPC and DMPG, DMPS MLVs which have not been ex-
tensively annealed at low temperatures display only a single gel-
to-liquid crystalline endothermic phase transition on heating.
The pattern observed for the gel-to-liquid crystalline phase
transition of DMPS in the presence of the truncated-LLP3
peptide was qualitatively similar to those found for DMPC and
DMPG (Fig. 5D), indicating in all cases a lateral segregation
of different phases within the plane of the bilayer. The co-
existence of at least two phases would indicate that one of
them would be enriched in peptide (phospholipids highly dis-
turbed) whereas the other one would be impoverished in them
(phospholipids slightly disturbed).
Fig. 5. DSC heating thermograms for mixtures of (A) DEPE, (B) DMPC, (C) DMPG and (D) DMPS in the presence of the truncated-LLP3 peptide at different peptide
to phospholipid molar ratios. The phospholipid/peptide molar ratio is shown on the curves. All the thermograms are normalized to the same amount of lipid.
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peptide induced by membrane binding has been studied by
analyzing the infrared Amide I′ band located between 1700 and
1600 cm− 1 in membranes by Fourier transformed infrared
spectroscopy (FTIR). The maximum of the Amide I' band did
not change significantly upon increasing the temperature either
in the absence or in the presence of model membranes com-
posed of either DMPC, DMPA POPC or POPC/Chol at a molar
ratio of 2:1, suggesting a high degree of conformational stabi-
lity of the peptide (not shown for briefness). Applying self-
deconvolution and derivation to the Amide I' band of the
peptide in solution [46,47], we have identified different com-
ponent bands at frequencies of about 1689, 1671, 1656, 1644,
and 1631 cm− 1, being the 1644 cm− 1 band the main one.Similar component bands and intensities were found in all the
membrane samples studied, implying that random structure was
the main secondary structure of the peptide in all the systems;
furthermore, the binding of the peptide to the membrane bilayer
did not affect its structure. Random structure was also the main
secondary structure as observed by CD; however, the peptide
displayed about 80% α-helix in the presence of 70% TFE (not
shown).
4. Discussion
The membrane fusion protein of HIV-1 is the envelope
transmembrane gp41 glycoprotein and it is thought that seve-
ral gp41 proteins are capable of juxtaposing, destabilizing and
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formed [56–59]. A lot of research on viral membrane fusion
proteins point out the existence of several regions which are
involved in the viral fusion process. We have shown recently the
existence of different membranotropic regions in gp41 by using a
peptide library encompassing the full sequence of the envelope
glycoprotein gp41, i.e., both ecto and endodomains [1,2,11].
Heretofore there has been a significant number of biophysi-
cal studies on different membrane-active regions along the
gp41 ectodomain, such as the fusion peptide, the N-heptad re-
peat region, the loop and the pre-transmembrane domains
[8,9,12,49,60–62], all of them involved in accomplishing the
gp41 fusion process [2]. Regarding the gp41 endodomain, it is
known the existence of different membrane-active regions,
known as the lentivirus lytic peptides or LLPs [27,28,30]. Their
biological function is still unclear, although they could have a
role on either pore formation and stabilization, viral budding or
might be both of them. However, it should be also taken into
account that it has been reported that truncations of the cyto-
plasmic tail of gp41 increase the efficiency of fusogenicity [26].
According to our recent study about the membranotropic re-
gions along gp41 [11], we have found that the most membrano-
tropic region along the full sequence of gp41 is located in the so
called LLP-3 region (Fig. 1). This region contains a leucine zipper
which is highly conserved in numerous HIV-1 strains, and in
addition, it has a region rich in aromatic residues, since it includes
four tryptophans and two tyrosines. Specifically, only one work
describing some biophysical features of the LLP-3 region has
been reported previously [30]. The 27-mer peptide used in that
work encompasses the whole peptide studied here, except the four
first residues. In the present work we present a thorough and
complementary biophysical study of the membrane interaction of
a peptide derived from LLP3, selected from the membranotropic
region map (see Fig. 1), the so called truncated-LLP3 peptide.
According to the matrixes displayed in Fig. 1, which were
constructed using hydrophobic, interfacial and hydrophobic
moment indexes as well as taking into account the secondary
structure of the protein [11,63–67], we can observe a surface
patch corresponding to the truncated-LLP3 peptide with high
bilayer-to-water transfer free-energy values. Accordingly, the
truncated-LLP3 peptide studied in this work partitions with a
high affinity to model membranes having different phospholipid
compositions. We and others have previously found similar
binding affinities for other peptides pertaining to other proteins
as reported previously [8,9,12,44,46,49,61,68]. The main bind-
ing force was apparently from an electrostatic origin, presu-
mably owing to the net charge of +1 for each peptide, since
the truncated-LLP3 peptide showed a higher affinity for anionic-
phospholipid compositions than those containing zwitteronic
phospholipids. This was further demonstrated by hydrophilic
and lipophylic probe quenching, suggesting that the truncated-
LLP3 peptide was effectively incorporated into the membranes,
located at the membrane interface, but nearer to the interface
in the presence of negatively-charged phospholipids.
The truncated-LLP3 peptide was also capable of altering
the stability of the membrane causing the release of fluorescent
probes. This effect was dependent on the lipid compositionand on the lipid/peptide molar ratio, being the highest effect
observed for liposomes containing EPC, Chol and SM. Lower
but significant values were observed for other liposome com-
positions, which might be due to the fact that the positively-
charged peptide has an increased affinity for negatively-charged
liposomes, favoring an upper location of the peptide at the
membrane interface, therefore decreasing its leakage-effect. The
observed leakage-effect could be due primarily to hydrophobic
interactions within the bilayer but not to the specific charge of
the phospholipid headgroups. On the other hand, according to
peptide disaggregation assays, the truncated-LLP3 peptide is a
hydrophobic peptide which disaggregates after interacting with
the membrane, probably in its monomeric form. Once the
truncated-LLP3 peptide is in its monomeric form it can enter
into the membrane oligomerizing. It is interesting to note that it
has been shown the self-assembling potential of the C-terminal
part of gp41 to form a high order multimer [69,70].
Interestingly, the truncated-LLP3 peptide was able of affec-
ting the lamellar fluid to hexagonal HII phase transition of DEPE,
with a concomitant increase in the Lα–HII phase transition for
several molar lipid/peptide ratios. According to the classification
of proteins and peptides regarding their interaction with phos-
pholipid bilayers based on thermotropic characteristics [71,72],
we could classify the truncated-LLP3 peptide as a peptide of
group II. For all assayed phospholipids and at increasing peptide
concentrations we observed a significant decrease in cooperati-
vity, as well as a decrease in Tm and in enthalpy. These features
would indicate that the truncated-LLP3 peptide would interact
with the membrane through both electrostatic and hydrophobic
effects and it would be adsorbed at the membrane interface,
although it would be possible that part of the peptide could be
inserted deeper than the membrane interface, increasing in
this way the membrane permeability. It is worth to note that,
differently to the results obtained by Kliger and Shai [30] and
according to our infrared results, the truncated-LLP3 peptide
adopted mainly a random structure (∼40%), but also a significant
amount of α-helical and β-structures (∼22–23% each one) in the
presence of either zwitterionic or anionic phospholipids, even at
different lipid/peptide ratios. Taking together all these data, it
could be envisaged that the truncated-LLP3 peptide begins to
disaggregate in the presence of membranes, adopting mainly a
random structure, although it could also adopt an α-helical
structure, at least in part of the peptide structure.
The possibility that the Kennedy sequence pertaining to the
gp41 endodomain could be part of an external loop structure [73]
and the membrane-perturbing properties of LLP3, in particular,
and LLPs in general, open the possibility that these domains
might function in modulating the membrane fusion events,
synergistically with other membranotropic regions pertaining to
the gp41 ectodomain.
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